Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525336 | 0.75 | ADORA2A (0.51) | SMN1; SMN2TSHRMAPK14TNFCYP11B1 | |
| SCHEMBL27663449 | 0.75 | MAPK14 (0.48) | SMN1; SMN2HPGDTSHRMAPK14TNF | |
| SCHEMBL29044749 | 0.75 | KDM4C (0.48) | SMN1; SMN2TSHRMAPK14TNFCYP11B1 | |
| SCHEMBL3523300 | 0.75 | GAA (0.50) | SMN1; SMN2TSHRMAPK14TNFCYP11B1 | |
| SCHEMBL4478552 | 0.73 | MAPK14 (0.52) | SMN1; SMN2HPGDALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3521393 | 0.72 | MAPK14 (0.58) | SMN1; SMN2HPGDTSHRALDH1A1KMT2A | |
| SCHEMBL11788419 | 0.72 | PKM (0.45) | SMN1; SMN2TSHRMAPK14TNFCYP11B1 | |
| SCHEMBL1529051 | 0.72 | YTHDC1 (0.46) | SMN1; SMN2TSHRMAPK14TNFCYP11B1 | |
| SCHEMBL3519801 | 0.71 | ALDH1A1 (0.50) | SMN1; SMN2HPGDNPC1TSHRRAB9A | |
| SCHEMBL3522503 | 0.71 | ALDH1A1 (0.50) | SMN1; SMN2HPGDNPC1TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | ABL1 75/4885RIN1 783/4885SMN1; SMN2 912/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | ABL1 125/4885RIN1 750/4885SMN1; SMN2 746/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | ABL1 75/4885RIN1 783/4885SMN1; SMN2 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.